Table 2 Treatment effects
Variable | Group one (Vs. basal-bolus) | Group two (Vs. Basal insulin + GLP-1RA) | |||
|---|---|---|---|---|---|
|  | IDegLira | Basal-bolus | IDegLira | Basal + GLP-1RA | Basal-bolus |
HbA1c (%) | -1.5 [18] | -1.5 [18] | -1.68 [19] | -1.33* [19] | -1.39* [19] |
SBP (mmHg) | -4.5 [18] | -1.2 [18] | -6.84 [19] | -4.68 [19] | 1.83* [19] |
TC (mmol/L) | -0.18 [18] | 0.06 [18] | -0.27 [19] | -0.34 [19] | -5.80 [19] |
LDL (mmol/L) | -0.05 [18] | 0.06 [18] | -0.20 [19] | -0.25 [19] | -0.08 [19] |
HDL (mmol/L) | 0 [18] | 0.05 [18] | 0.01 [19] | -0.02 [19] | 0.01 [19] |
TG (mmol/L) | -0.21 [18] | -0.12 [18] | -0.21 [19] | -0.19 [19] | -0.18 [19] |
BMI (kg/m2) | -1.02 [19] | 1.42* [19] | -1.02 [19] | -1.27 [19] | 1.42* [19] |
Mild hypoglycemia (PYE) | 0.9016 [18] | 7.8443 [18] | 1.219 [19] | 1.241 [19] | 10.563* [19] |
Severe hypoglycemia (PYE) | 0.03 [18] | 0.08 [18] | 0.004 [9] | 0 [9] | 0.024 [19] |